ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 194 filers reported holding ENANTA PHARMACEUTICALS INC in Q2 2019. The put-call ratio across all filers is 2.98 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $27,172,150 | -25.7% | 2,095,000 | 0.0% | 0.13% | -22.9% |
| Q1 2024 | $36,578,700 | +92.0% | 2,095,000 | +3.5% | 0.17% | +84.4% |
| Q4 2023 | $19,055,250 | -9.0% | 2,025,000 | +8.0% | 0.09% | -8.2% |
| Q3 2023 | $20,943,750 | -47.8% | 1,875,000 | 0.0% | 0.10% | -51.2% |
| Q2 2023 | $40,125,000 | -36.0% | 1,875,000 | +21.0% | 0.20% | -41.2% |
| Q1 2023 | $62,682,000 | -13.1% | 1,550,000 | 0.0% | 0.34% | -19.7% |
| Q4 2022 | $72,106,000 | -10.3% | 1,550,000 | 0.0% | 0.43% | -3.6% |
| Q3 2022 | $80,399,000 | +9.7% | 1,550,000 | 0.0% | 0.44% | +11.3% |
| Q2 2022 | $73,269,000 | -33.6% | 1,550,000 | 0.0% | 0.40% | -25.5% |
| Q1 2022 | $110,329,000 | -6.3% | 1,550,000 | -1.5% | 0.53% | -9.4% |
| Q4 2021 | $117,691,000 | +3.8% | 1,573,829 | -21.1% | 0.59% | +11.2% |
| Q3 2021 | $113,336,000 | +29.1% | 1,995,000 | 0.0% | 0.53% | +47.8% |
| Q2 2021 | $87,800,000 | -10.8% | 1,995,000 | 0.0% | 0.36% | -26.8% |
| Q1 2021 | $98,393,000 | +31.7% | 1,995,000 | +12.4% | 0.49% | +8.9% |
| Q4 2020 | $74,728,000 | -8.0% | 1,775,000 | 0.0% | 0.45% | -20.1% |
| Q3 2020 | $81,260,000 | -7.5% | 1,775,000 | +1.4% | 0.56% | -20.1% |
| Q2 2020 | $87,868,000 | -2.4% | 1,750,000 | 0.0% | 0.70% | -9.1% |
| Q1 2020 | $90,003,000 | -16.8% | 1,750,000 | 0.0% | 0.77% | +5.9% |
| Q4 2019 | $108,115,000 | +41.2% | 1,750,000 | +37.3% | 0.73% | +26.3% |
| Q3 2019 | $76,555,000 | -5.5% | 1,274,212 | +32.7% | 0.58% | +9.7% |
| Q2 2019 | $81,005,000 | -9.8% | 960,000 | +2.1% | 0.53% | -21.9% |
| Q1 2019 | $89,789,000 | +37.0% | 940,000 | +1.6% | 0.68% | +40.6% |
| Q4 2018 | $65,518,000 | -11.6% | 925,000 | +6.6% | 0.48% | +9.6% |
| Q3 2018 | $74,137,000 | -40.5% | 867,500 | -19.3% | 0.44% | -43.0% |
| Q2 2018 | $124,593,000 | +68.3% | 1,075,000 | +17.5% | 0.77% | +49.9% |
| Q1 2018 | $74,033,000 | +36.4% | 915,000 | -1.1% | 0.51% | +16.3% |
| Q4 2017 | $54,279,000 | +181.3% | 925,000 | +124.3% | 0.44% | +156.4% |
| Q3 2017 | $19,297,000 | – | 412,333 | – | 0.17% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 519,035 | $60,156,000 | 15.36% |
| Matarin Capital Management, LLC | 201,703 | $23,377,378,000 | 1.69% |
| ARMISTICE CAPITAL, LLC | 124,000 | $14,372,000 | 0.94% |
| Sapphire Star Partners LP | 7,803 | $904,000 | 0.93% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 98,631 | $11,431,000 | 0.83% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,075,000 | $124,593,000 | 0.77% |
| Granahan Investment Management | 100,670 | $11,668,000 | 0.70% |
| Virtus ETF Advisers LLC | 6,577 | $762,000 | 0.67% |
| AlphaMark Advisors, LLC | 11,115 | $1,288,000 | 0.52% |
| Ativo Capital Management LLC | 15,029 | $1,742,000 | 0.48% |